Please assess the completion status of the following clinical trial:

Trial Title: REMission INDuction in Very Early Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fulfilling 2010 ACR/EULAR criteria for RA.~* Patient reported symptom duration \< 12 months~* Naïve for DMARD and biological treatment~* Naïve for previous use of glucocorticoids for RA~* DAS28 ≥3.2~Exclusion Criteria:~* Being pregnant or being a nursing women or a women of child bearing potential without (adequate) use of contraception~* Having any other inflammatory rheumatic disease than RA, except for secondary Sjögren's syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Taper methotrexate, then golimumab (Type: EXPERIMENTAL): Taper methotrexate 25\>0mg/wk during 24 weeks, then, if still in sustained remission, taper golimumab 50\>0mg/month during 24 weeks.
- Taper golimumab, then methotrexate (Type: ACTIVE_COMPARATOR): Taper golimumab 50\>0mg/month during 24 weeks, then, if still in sustained remission, taper methotrexate 25\>0mg/wk during 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).